AKTS

Aktis Oncology, Inc.$14.18-1.75 (-10.99%)

Prev Close$15.93·MCap$884.1M·P/E—·Vol352.8K·Yield—

▲

Buys (12M)

$39.25M

▼

Sells (12M)

$258.6K

◆

Net Activity

Net Buyer

$38.99M

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at Aktis Oncology, Inc. (AKTS) has been dominated by buying, with 3 insider purchases totaling $39.25M and 1 insider sale totaling $258.6K. The most recent insider transaction was by Czibere Akos (officer: Chief Medical Officer), who sold $258.6K worth of shares on Sep 24, 2026. Aktis Oncology, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $884.1M.

AKTS Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Sep 24, 2026	Czibere Akos	officer: Chief Medical Officer	Sell	12,500	$20.69	$258.6K	7,401-63%
Jan 12, 2026	Foley Todd	Director	Buy	232,870	$18.00	$4.19M	0
Jan 12, 2026	GADICKE ANSBERT	10% Owner	Buy	1,112,777	$18.00	$20.03M2.1% OS	0
Jan 12, 2026	Kim Helen Susan	Director	Buy	835,000	$18.00	$15.03M1.6% OS	0

AKTS Insider Buying Activity

The following table shows recent insider purchases of Aktis Oncology, Inc. (AKTS) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value
Jan 12, 2026	Foley Todd	Director	Buy	232,870	$18.00	$4.19M
Jan 12, 2026	GADICKE ANSBERT	10% Owner	Buy	1,112,777	$18.00	$20.03M2.1% OS
Jan 12, 2026	Kim Helen Susan	Director	Buy	835,000	$18.00	$15.03M1.6% OS